Liver-Kidney treatment response under review

NCT ID NCT06161766

Completed Knowledge-focused Sponsor: University Hospital Freiburg Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study from University Hospital Freiburg looked back at 490 patients with liver cirrhosis and signs of chronic kidney disease who were treated for hepatorenal syndrome. Researchers compared how well patients with and without pre-existing kidney disease responded to vasoactive drugs (terlipressin or noradrenalin) plus albumin. The goal was to understand treatment outcomes and help guide future care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: terlipressin or noradrenalin plus albumin
What this could lead to: If successful, this could help doctors better identify which patients with liver and kidney problems are most likely to benefit from vasoactive treatment.
What could go wrong: This is a retrospective study, meaning it looks back at past data, so it cannot prove cause and effect. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome cirrhosis of liver hepatorenal syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASES HEPATO-RENAL SYNDROME LIVER CIRRHOSIS

Contacts and locations

Locations

University Hospital Münster

Münster, Germany
University Medical Center Freiburg

Freiburg im Breisgau, Germany
University Medical Center Mainz

Mainz, Germany
University Medical center Jena

Jena, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.